Tharimmune, Inc. (Nasdaq: THAR), a clinical-stage biotechnology company focused on advancing therapies in immunology and inflammation, has successfully closed its previously announced $1.74 million registered direct offering of securities to institutional investors under its effective shelf registration statement.
The offering consisted of 414,331 shares of common stock, 559,910 pre-funded warrants to purchase common stock, and 974,241 common warrants with an exercise price of $1.66 per share. Each unit, comprised of one share (or pre-funded warrant) and one common warrant, was priced at $1.786.
Lucosky Brookman LLP served as legal counsel to Tharimmune.
